PARP Inhibition: The New Frontier in Recurrent Ovarian Cancer

Program Goals

BRCA Testing in Ovarian Cancer NCCN, ASCO, ESMO, SGO Guidance

Olaparib: FDA Accelerated Approval

Olaparib Indications: US vs Europe

PARP Inhibitors: Common Adverse Events

Supportive Care to Maintain Patients on PARPi

Ongoing PARP Inhibitor Trials

Proposed Front-line Veliparib Study (GOG 3005)

Olaparib Plus Cediranib

PARPi Combinations: Recurrent Ovarian Cancer

Homologous Recombination Deficiency and "BRCAness"

ARIEL2: Rucaparib Sensitivity According to Prospectively Defined Molecular Subgroups

ARIEL2: Response by HRD Status

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)